4.6
CiteScore
2.2
Impact Factor
- ISSN 1674-8301
- CN 32-1810/R
4.6
2.2
| Citation: |
Daohong Chen. Untoward immune effects of modern medication[J]. The Journal of Biomedical Research, 2024, 38(1): 17-23. DOI: 10.7555/JBR.37.20230071
|
Immune-related adverse events (irAEs) represent an increasingly concerning challenge in the assessment of biopharmaceutical products. In contrast to historically rare allergic reactions associated with small chemical drugs, contemporary biotherapeutics exhibit a significantly higher morbidity of irAEs, because of their complex structure and comprehensive mechanisms of action. While the immunogenicity of protein-based compounds is associated with the induction of anti-drug antibodies, the pathogenesis of irAEs in advanced biologics, such as cell and gene therapy, remains to be further delineated. In the current study, I present an updated profile regarding the untoward immune effects of medications, covering various material categories systematically, with the underlying mechanisms to inspire risk mitigation in biopharmaceutical development and application.
I thank my colleagues for their encouragement.
CLC number: R967, Document code: A
The authors reported no conflict of interests.
| [1] |
Warrington R, Silviu-Dan F, Wong T. Drug allergy[J]. Allergy Asthma Clin Immunol, 2018, 14(S2): 60. doi: 10.1186/s13223-018-0289-y
|
| [2] |
Chen D, Qi EY. Innovative highlights of clinical drug trial design[J]. Transl Res, 2020, 224: 71–77. doi: 10.1016/j.trsl.2020.05.007
|
| [3] |
Shakhnovich V, Meibohm B, Rosenberg A, et al. Immunogenicity in clinical practice and drug development: when is it significant?[J]. Clin Transl Sci, 2020, 13(2): 219–223. doi: 10.1111/cts.12717
|
| [4] |
Tourdot S, Abdolzade-Bavil A, Bessa J, et al. 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals[J]. mAbs, 2020, 12(1): 1725369. doi: 10.1080/19420862.2020.1725369
|
| [5] |
Chen D, Zhang X. Cellular immunity augmentation in mainstream oncologic therapy[J]. Cancer Biol Med, 2017, 14(2): 121–128. doi: 10.20892/j.issn.2095-3941.2017.0022
|
| [6] |
Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS)[J]. Int J Mol Sci, 2021, 22(4): 2147. doi: 10.3390/ijms22042147
|
| [7] |
Lee S, Raw A, Yu L, et al. Scientific considerations in the review and approval of generic enoxaparin in the United States[J]. Nat Biotechnol, 2013, 31(3): 220–226. doi: 10.1038/nbt.2528
|
| [8] |
Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination[J]. N Engl J Med, 2021, 384(23): 2202–2211. doi: 10.1056/NEJMoa2105385
|
| [9] |
Chen D. Real-world studies: bridging the gap between trial-assessed efficacy and routine care[J]. J Biomed Res, 2022, 36(3): 147–154. doi: 10.7555/JBR.36.20220040
|
| [10] |
Castells M, Khan DA, Phillips EJ. Penicillin allergy[J]. N Engl J Med, 2019, 381(24): 2338–2351. doi: 10.1056/NEJMra1807761
|
| [11] |
Markóth C, File I, Szász R, et al. Ibrutinib-induced acute kidney injury via interstitial nephritis[J]. Ren Fail, 2021, 43(1): 335–339. doi: 10.1080/0886022X.2021.1874985
|
| [12] |
Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management[J]. Crit Care, 2017, 21(1): 89. doi: 10.1186/s13054-017-1678-1
|
| [13] |
Stocco G, Lucafò M, Decorti G. Pharmacogenomics of antibiotics[J]. Int J Mol Sci, 2020, 21(17): 5975. doi: 10.3390/ijms21175975
|
| [14] |
Cheng C, Su SC, Chen C, et al. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review[J]. J Immunol Res, 2014, 2014: 565320. doi: 10.1155/2014/565320
|
| [15] |
Mayorga C, Montañez MI, Najera F, et al. The role of benzylpenicilloyl epimers in specific IgE recognition[J]. Front Pharmacol, 2021, 12: 585890. doi: 10.3389/fphar.2021.585890
|
| [16] |
Khan DA, Banerji A, Bernstein JA, et al. Cephalosporin allergy: current understanding and future challenges[J]. J Allergy Clin Immunol Pract, 2019, 7(7): 2105–2114. doi: 10.1016/j.jaip.2019.06.001
|
| [17] |
Meunier S, de Bourayne M, Hamze M, et al. Specificity of the T cell response to protein biopharmaceuticals[J]. Front Immunol, 2020, 11: 1550. doi: 10.3389/fimmu.2020.01550
|
| [18] |
Zinsli LV, Stierlin N, Loessner MJ, et al. Deimmunization of protein therapeutics—Recent advances in experimental and computational epitope prediction and deletion[J]. Comput Struct Biotechnol J, 2020, 19: 315–329. doi: 10.1016/j.csbj.2020.12.024
|
| [19] |
Hu X, Chen F. Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients[J]. Endocr Connect, 2018, 7(1): R47–R55. doi: 10.1530/EC-17-0309
|
| [20] |
Susantad T, Fuangthong M, Tharakaraman K, et al. Modified recombinant human erythropoietin with potentially reduced immunogenicity[J]. Sci Rep, 2021, 11(1): 1491. doi: 10.1038/s41598-020-80402-1
|
| [21] |
Khalilian S, Motovali-Bashi M, Rezaie H. Factor Ⅷ: perspectives on immunogenicity and tolerogenic strategies for hemophilia A patients[J]. Int J Mol Cell Med, 2020, 9(1): 33–50. doi: 10.22088/IJMCM.BUMS.9.1.33
|
| [22] |
Chen D. Dual targeting autoimmunity and cancer: from biology to medicine[J]. J Clin Pharmacol, 2018, 58(8): 990–996. doi: 10.1002/jcph.1100
|
| [23] |
Parikh CR, Ponnampalam JK, Seligmann G, et al. Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults[J]. Ther Adv Musculoskelet Dis, 2021, 13: 1759720X211002685. doi: 10.1177/1759720X211002685
|
| [24] |
Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance[J]. Targ Oncol, 2020, 15(4): 449–466. doi: 10.1007/s11523-020-00738-6
|
| [25] |
Dougan M, Luoma AM, Dougan SK, et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy[J]. Cell, 2021, 184(6): 1575–1588. doi: 10.1016/j.cell.2021.02.011
|
| [26] |
Socinski MA, Jotte RM, Cappuzzo F, et al. Association of immune-related adverse events with efficacy of Atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials[J]. JAMA Oncol, 2023, 9(4): 527–535. doi: 10.1001/jamaoncol.2022.7711
|
| [27] |
Baldo B. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses[J]. OncoImmunology, 2013, 2(10): e26333. doi: 10.4161/onci.26333
|
| [28] |
Davda J, Declerck P, Hu-Lieskovan S, et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics[J]. J Immunother Cancer, 2019, 7(1): 105. doi: 10.1186/s40425-019-0586-0
|
| [29] |
Lei W, Xie M, Jiang Q, et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and Meta-analysis[J]. Cancers, 2021, 13(15): 3912. doi: 10.3390/cancers13153912
|
| [30] |
Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment[J]. Int J Mol Sci, 2021, 22(14): 7652. doi: 10.3390/ijms22147652
|
| [31] |
Wright A, Arthaud-Day ML, Weiss ML. Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species[J]. Front Cell Dev Biol, 2021, 9: 632717. doi: 10.3389/fcell.2021.632717
|
| [32] |
Fang YH, Wang SPH, Chang HY, et al. Immunogenicity in stem cell therapy for cardiac regeneration[J]. Acta Cardiol Sin, 2020, 36(6): 588–594. doi: 10.6515/ACS.202011_36(6).20200811A
|
| [33] |
Ciurea SO, Al Malki MM, Kongtim P, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2020, 55(1): 12–24. doi: 10.1038/s41409-019-0499-z
|
| [34] |
Chen D. Heparin beyond anti-coagulation[J]. Curr Res Transl Med, 2021, 69(4): 103300.
|
| [35] |
Salter BS, Weiner MM, Trinh MA, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review[J]. J Am Coll Cardiol, 2016, 67(21): 2519–2532. doi: 10.1016/j.jacc.2016.02.073
|
| [36] |
Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity[J]. Blood, 2007, 110(13): 4253–4260. doi: 10.1182/blood-2007-08-105098
|
| [37] |
Arepally GM. Heparin-induced thrombocytopenia[J]. Blood, 2017, 129(21): 2864–2872. doi: 10.1182/blood-2016-11-709873
|
| [38] |
Kim HS, Kim H, Jeong YJ, et al. Comparative analysis of the suspected heparin-induced thrombocytopenia level in Korea[J]. Basic Clin Pharmacol Toxicol, 2017, 121(4): 360–367. doi: 10.1111/bcpt.12791
|
| [39] |
He Y, He H, Liu D, et al. Fondaparinux in a critically ill patient with heparin-induced thrombocytopenia: a case report[J]. Medicine, 2018, 97(7): e12236. doi: 10.1097/MD.0000000000012236
|
| [40] |
Chen D, Goswami CP, Burnett RM, et al. Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle[J]. Cancer Res, 2014, 74(16): 4270–4281. doi: 10.1158/0008-5472.CAN-13-2817
|
| [41] |
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2-preliminary report[J]. N Engl J Med, 2020, 383(20): 1920–1931. doi: 10.1056/NEJMoa2022483
|
| [42] |
Golob JL, Lugogo N, Lauring AS, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration[J]. JCI Insight, 2021, 6(9): e149187. doi: 10.1172/jci.insight.149187
|
| [43] |
Singh B, Kaur P, Cedeno L, et al. COVID-19 mRNA vaccine and myocarditis[J]. Eur J Case Rep Intern Med, 2021, 8(7): 002681. doi: 10.12890/2021_002681
|
| [44] |
Akiyama H, Kakiuchi S, Rikitake J, et al. Immune thrombocytopenia associated with Pfizer-BioNTech's BNT162b2 mRNA COVID-19 vaccine[J]. IDCases, 2021, 25: e01245. doi: 10.1016/j.idcr.2021.e01245
|
| [45] |
Wang Y, Zhang Z, Luo J, et al. mRNA vaccine: a potential therapeutic strategy[J]. Mol Cancer, 2021, 20(1): 33. doi: 10.1186/s12943-021-01311-z
|
| [46] |
He X, Urip BA, Zhang Z, et al. Evolving AAV-delivered therapeutics towards ultimate cures[J]. J Mol Med, 2021, 99(5): 593–617. doi: 10.1007/s00109-020-02034-2
|
| [47] |
Buscara L, Gross DA, Daniele N. Of rAAV and men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back[J]. J Pers Med, 2020, 10(4): 258. doi: 10.3390/jpm10040258
|
| [48] |
Li C, Goudy K, Hirsch M, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer[J]. Proc Natl Acad Sci U S A, 2009, 106(26): 10770–10774. doi: 10.1073/pnas.0902269106
|
| [49] |
Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination[J]. N Engl J Med, 2021, 384(22): 2092–2101. doi: 10.1056/NEJMoa2104840
|
| [50] |
Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination[J]. N Engl J Med, 2021, 384(22): 2124–2130. doi: 10.1056/NEJMoa2104882
|
| [51] |
Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species[J]. Cell, 2021, 184(19): 4919–4938.e22. doi: 10.1016/j.cell.2021.08.028
|
| [52] |
Fischer MD, Michalakis S, Wilhelm B, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial[J]. JAMA Ophthalmol, 2020, 138(6): 643–651. doi: 10.1001/jamaophthalmol.2020.1032
|
| [53] |
Jawa V, Terry F, Gokemeijer J, et al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020[J]. Front Immunol, 2020, 11: 1301. doi: 10.3389/fimmu.2020.01301
|
| [54] |
Ringdén O, Moll G, Gustafsson B, et al. Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of graft-versus-host disease, hemorrhages and acute respiratory distress syndrome[J]. Front Immunol, 2022, 13: 839844. doi: 10.3389/fimmu.2022.839844
|
| [55] |
Tang K, Seo J, Tiu BC, et al. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy[J]. JAMA Dermatol, 2022, 158(2): 189–193. doi: 10.1001/jamadermatol.2021.5476
|
| [56] |
Lin H, Cheng J, Mu W, et al. Advances in universal CAR-T cell therapy[J]. Front Immunol, 2021, 12: 744823. doi: 10.3389/fimmu.2021.744823
|
| [57] |
Vivarelli S, Falzone L, Leonardi GC, et al. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)[J]. Int J Oncol, 2021, 59(3): 75. doi: 10.3892/ijo.2021.5255
|
| [1] | Ruyu Wang, Haoran Wang, Junyu Mu, Hua Yuan, Yongchu Pang, Yuli Wang, Yifei Du, Feng Han. Molecular events in the jaw vascular unit: A traditional review of the mechanisms involved in inflammatory jaw bone diseases[J]. The Journal of Biomedical Research, 2023, 37(5): 313-325. DOI: 10.7555/JBR.36.20220266 |
| [2] | Weixi Feng, Yanli Zhang, Peng Sun, Ming Xiao. Acquired immunity and Alzheimer's disease[J]. The Journal of Biomedical Research, 2023, 37(1): 15-29. DOI: 10.7555/JBR.36.20220083 |
| [3] | Liu Shuying, Lu Shan. Antibody responses in COVID-19 patients[J]. The Journal of Biomedical Research, 2020, 34(6): 410-415. DOI: 10.7555/JBR.34.20200134 |
| [4] | Park Ho-Eun, Do Kyung-Hyo, Lee Wan-Kyu. The immune-modulating effects of viable Weissella cibaria JW15 on RAW 264.7 macrophage cells[J]. The Journal of Biomedical Research, 2020, 34(1): 36-43. DOI: 10.7555/JBR.33.20190095 |
| [5] | Huijeong Ahn, Hyuk Moo Kwon, Eunsong Lee, Pyeung-Hyeun Kim, Eui-Bae Jeung, GeunShik Lee. Role of inflammasome regulation on immune modulators[J]. The Journal of Biomedical Research, 2018, 32(6): 401-410. DOI: 10.7555/JBR.32.20170120 |
| [6] | Arbind Kumar Choudhary, Rathinasamy Sheela Devi. Effects of aspartame on hsp70, bcl-2 and bax expression in immune organs of Wistar albino rats[J]. The Journal of Biomedical Research, 2016, 30(5): 427-435. DOI: 10.7555/JBR.30.20140097 |
| [7] | Min Zhang, Huiwei He, Ze-Mu Wang, Zhihui Xu, Ningtian Zhou, Zhengxian Tao, Bo Chen, Chunjian Li, Tiebing Zhu, Di Yang, Liansheng Wang, Zhijian Yang. Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study[J]. The Journal of Biomedical Research, 2014, 28(2): 98-107. DOI: 10.7555/JBR.28.20130124 |
| [8] | Aixia Zhang, Brian Cao. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA[J]. The Journal of Biomedical Research, 2012, 26(6): 467-473. DOI: 10.7555/JBR.26.20120057 |
| [9] | Lingjun Li, Pengcheng Ma, Yuping Cao, Lei Tao, Yue Tao. Single-dose and multiple-dose pharmacokinetics of zaltoprofen after oral administration in healthy Chinese volunteers[J]. The Journal of Biomedical Research, 2011, 25(1): 56-62. DOI: 10.1016/S1674-8301(11)60007-9 |
| [10] | Xinjian Liu, Xiaomin Feng, Qi Tang, Zhongcan Wang, Zhenning Qiu, Yuhua Li, Changjun Wang, Zhenqing Feng, Jin Zhu, Xiaohong Guan. Characterization and potential diagnostic application of monoclonal antibodies specific to rabies virus[J]. The Journal of Biomedical Research, 2010, 24(5): 395-403. DOI: 10.1016/S1674-8301(10)60053-X |
Figures(1) / Tables(1)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
Authors and Reviewers
DownLoad: